On this page
OSTM1
osteoclastogenesis associated transmembrane protein 1
OSTM1 is located on the long (q) arm of chromosome 6, at band 6q21. Arm ratio per GRCh38 - banding schematic.
Explore chromosome 6 in the library →Available at Jeen Health
Clinical tests that include this
Overview
OSTM1 (osteoclastogenesis associated transmembrane protein 1) is located on chromosome 6q21 and encodes a 334-amino acid transmembrane protein essential for bone homeostasis. The protein plays a critical role in osteoclast function, particularly in maintaining the acidic environment required for bone resorption. In healthy bone tissue, osteoclasts continuously break down old bone matrix whilst osteoblasts lay down new bone, ensuring skeletal strength and mineral balance.
Pathogenic variants in OSTM1 are inherited in an autosomal recessive pattern, meaning that affected individuals carry two altered copies of the gene. These variants disrupt normal bone remodelling processes, leading to severe skeletal and neurological complications in early life.
What the gene does
The OSTM1 protein functions primarily in osteoclasts, where it associates with the vacuolar proton pump complex responsible for acidifying the resorption lacuna - the sealed compartment between the osteoclast and bone surface. This acidic microenvironment is essential for dissolving hydroxyapatite crystals in the bone matrix and activating enzymes that degrade organic bone components.
Beyond its skeletal role, OSTM1 contributes to lysosomal function in various cell types, particularly neurons and melanocytes. The protein helps maintain proper lysosomal pH, which is critical for the degradation of cellular waste products and the processing of proteins. In the nervous system, OSTM1 supports neuronal survival by ensuring efficient lysosomal clearance of metabolic by-products. The protein's transmembrane architecture allows it to anchor within cellular membranes whilst coordinating with other components of the proton-pumping machinery.
Video: Genetics 101
Chromosome location
OSTM1 is located on the long arm of chromosome 6 at position 21 (6q21). The gene spans approximately 17 kilobases of genomic DNA and comprises 6 exons. This chromosomal region contains several genes involved in skeletal development and immune function, though OSTM1's specific role in osteoclastogenesis distinguishes it within this genomic neighbourhood.
Protein structure
Domain architecture has not been experimentally characterised in detail for this protein. The OSTM1 protein contains a predicted transmembrane segment that anchors it within cellular membranes, enabling its interaction with the vacuolar ATPase complex. Structural predictions suggest the protein adopts a topology that positions specific regions in the lysosomal lumen whilst others face the cytoplasm, facilitating its role in coordinating proton transport across membranes.
Key variants
Pathogenic variants in OSTM1 include missense changes, nonsense mutations, and small deletions that disrupt protein function. Most disease-causing variants impair the protein's ability to associate with the vacuolar ATPase complex or destabilise its membrane localisation. Because OSTM1-related conditions follow autosomal recessive inheritance, individuals typically carry one variant inherited from each parent.
Sample of pathogenic variants
10 pathogenic / likely-pathogenic variants from ClinVar, ranked by review status (expert-panel-reviewed first). This is a sample; recurrent founder variants in a specific population may not appear here - see the full ClinVar listing via the link above.
| Variant (HGVS) | Protein change | Classification | Evidence | Associated condition |
|---|---|---|---|---|
c.415_416del | p.Gln140fs | Pathogenic | ★★☆☆ | Autosomal recessive osteopetrosis 5 |
c.692dup | p.Ser232fs | Pathogenic | ★★☆☆ | Autosomal recessive osteopetrosis 5 |
c.796C>T | p.Arg266Ter | Pathogenic/Likely pathogenic | ★★☆☆ | not provided |
g.(?_108385369)_(108385523_?)del | - | Pathogenic | ★☆☆☆ | not provided |
g.(?_108395434)_(108395855_?)del | - | Pathogenic | ★☆☆☆ | not provided |
c.256G>T | p.Glu86Ter | Pathogenic | ★☆☆☆ | not provided |
c.498G>A | p.Trp166Ter | Pathogenic | ★☆☆☆ | not provided |
c.548C>G | p.Ser183Ter | Pathogenic | ★☆☆☆ | not provided |
c.551del | p.Asn184fs | Pathogenic | ★☆☆☆ | not provided |
c.811C>T | p.Arg271Ter | Pathogenic | ★☆☆☆ | Autosomal recessive osteopetrosis 5 |
Evidence stars indicate ClinVar review status. Individual variant interpretation should always be performed by a qualified clinical laboratory - many variants remain classified as Variants of Uncertain Significance (VUS) pending more research.
Associated conditions
Biallelic pathogenic variants in OSTM1 cause infantile malignant osteopetrosis with neurodegeneration, a severe condition presenting in the first months of life. Affected infants develop abnormally dense bones that are paradoxically fragile and prone to fracture. The impaired bone resorption leads to narrowed bone marrow cavities, resulting in anaemia, thrombocytopenia, and recurrent infections. Progressive neurological deterioration occurs due to lysosomal dysfunction in neurons, with features including vision loss from optic nerve compression, developmental regression, and seizures. The condition typically requires early haematopoietic stem cell transplantation to address the skeletal and haematological manifestations, though neurological complications may persist.
No disease links recorded for this gene in our reference set.
Inheritance pattern
Conditions caused by pathogenic OSTM1 variants typically follow autosomal recessive inheritance.
When both parents are carriers, each child has a 25% chance of being affected, 50% of being a carrier, and 25% of being unaffected.
UK clinical status
OSTM1 appears on multiple NHS Genomic Medicine Service gene panels with green classification, indicating strong evidence for clinical validity. The gene is included in the Osteopetrosis panel (R104.4), reflecting its established role in bone density disorders. OSTM1 also features on the Skeletal Dysplasia panel (R104), Hydrocephalus panel (R86), and Fetal Anomalies panel (green, R21), recognising the multi-system presentations that may prompt genetic testing. Additionally, OSTM1 was included in COVID-19 research panels, reflecting investigations into genetic factors influencing severe infection outcomes.
Sources: NHS GMS PanelApp · Genomics England PanelApp · NHS National Genomic Test Directory
Frequently asked questions
What does it mean to be a carrier of an OSTM1 variant?
Carriers have one pathogenic OSTM1 variant and one working copy of the gene, which is sufficient for normal bone and neurological function. Carriers do not develop osteopetrosis themselves but can pass the variant to their children. If both parents are carriers, each child has a 25% chance of inheriting two variants and developing the condition.
How is OSTM1-related osteopetrosis managed?
Management typically involves haematopoietic stem cell transplantation early in life to replace defective osteoclasts with healthy donor cells capable of normal bone resorption. Supportive care addresses complications such as infections, anaemia, and fractures. Neurological manifestations may require ongoing monitoring and intervention, as some features can persist despite successful transplantation.
Can genetic testing identify OSTM1 variants before symptoms appear?
Yes, carrier screening can identify individuals who carry one pathogenic OSTM1 variant, enabling informed reproductive planning. Prenatal and preimplantation genetic testing options are available for couples at risk of having an affected child, allowing early diagnosis before clinical features emerge.